Extensive research has confirmed that Eg5 is associated with and enables cancer progression in a variety of malignancies, including colorectal cancer, glioblastoma, and NSCLC, among others, emphasizing its potential clinical utility as a prognostic marker and therapeutic target [53]. This evidence concerns the gene KIF11 and non-small cell lung carcinoma.